Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2009

View Archived Issues

Genentech and Array BioPharma report novel Akt-1 protein kinase inhibitors

Oligomer-guanidine conjugates active against pain claimed by Nektar Therapeutics

GABA-A alpha5 receptor ligands for cognitive disorders presented by Roche

Simvastatin not beneficial in aneurysmal subarachnoid hemorrhage

Apixaban thromboprophylaxis and bleeding risk compared to those of enoxaparin

Biotie Therapies describes active metabolite of anti-inflammatory agent ELB-353

BMS reports development of its PPARalpha-selective dual agonist BMS-759509

Neurotune obtains approval for phase II dimiracetam trial in neuropathic pain

Advaxis to collaborate with City of Hope for leukemia and lymphoma vaccine

ActoGeniX receives grant to develop AG-013 for treatment of oral mucositis

FDA grants accelerated approval of Hiberix vaccine for Hib booster dose

11beta-HSD1 inhibitors for metabolic syndrome reported by Wyeth

Pfizer tests mGluR2 positive allosteric modulators in psychosis models

Glenmark discloses novel VR1 antagonists for the treatment of pain

Biovitrum AB reports the invention of 11beta-HSD1 inhibitors for glaucoma

Novel c-Met inhibitors designed at sanofi-aventis

Aska Pharmaceuticals describes novel PPAR activators

NIH develops novel PDE4 inhibitors for respiratory disorders

Quest launches influenza A H1N1 test in the U.S.

New indication for Helixate FS approved by FDA

Bristol-Myers Squibb reports second quarter 2009 results

Health Canada grants approval to Anika's Monovisc for osteoarthritis of the knee

Cel-Sci expands flu virus research program

The Medicines Company withdraws European MAA for oritavancin in cSSSI

Phase II trial of NeoFuse in lumbar spinal fusion surgery cleared by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...